STAT+: What Amazon Care’s nationwide expansion means for the telehealth industry
Amazon is officially starting its ascent to the national telehealth stage — and its nationwide…
Category: STAT+
STAT+: Translate Bio suffers a setback with mRNA-based treatment for cystic fibrosis
An inhaled mRNA-based treatment for patients with cystic fibrosis from Translate Bio failed to produce meaningful…
STAT+: Pharma wins a round in a battle with HHS over a drug discount program for hospitals
In a victory for the pharmaceutical industry, a federal judge temporarily blocked the federal government…
STAT+: Pharmalittle: Pfizer looks to raise price of Covid-19 shot after pandemic ends; FTC will be tougher on pharma mergers
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: Washington may become the second state to distribute its own generic drugs
A bill moving through the Washington legislature may make the state only the second in…
STAT+: 4 health startups racing to shake up diabetes care
If you’re a digital health startup looking to make an impact, it makes sense to…
.jpg)
STAT+: Pharma mergers face fresh scrutiny by a new international antitrust group
In response to a spate of pharmaceutical mergers, several antitrust regulators and enforcement agencies from…
STAT+: VC firm General Catalyst taps expertise of former Ancestry, Livongo, and Gilead executives
General Catalyst’s Hemant Taneja realized he had created a unique playbook for health care startups…
STAT+: Pharmalittle: More countries halt use of AstraZeneca Covid-19 vaccine; Moderna studies its shot in children
Rise and shine, another busy day is on the way. Most days are busy, though,…
STAT+: Google continues its wellness expansion with sleep sensing technology for Nest Hub
Google is turning another device into a wellness gadget. A month after introducing two health…
STAT+: Inside Color’s big — and highly bankrolled — pivot to public health tech
Mark Evans may just have the fastest tests in the west. In La Cañada, Calif.,…
STAT+: Xavier Becerra’s 4 most urgent challenges as Biden’s soon-to-be HHS secretary
WASHINGTON — Xavier Becerra has survived the worst of a tense confirmation battle to become…
STAT+: Once again, the viability of the U.S. biosimilar market is thrown into question
Despite periodic reports that biosimilars have finally arrived and will save the U.S. health care…
STAT+: In restarted study, Solid Bio reports no serious toxicity in Duchenne patient given ‘safer’ gene therapy
Solid Biosciences said Monday that it has restarted a clinical trial involving its experimental gene…
STAT+: Insulin makers win a significant round in Minnesota lawsuit accusing them of racketeering
In a setback to efforts to control insulin prices, a U.S. court judge tossed key…
STAT+: Insulin makers win a significant round in Minnesota lawsuit accusing them of racketeering
In a setback to efforts to control insulin prices, a U.S. court judge tossed key…
STAT+: A Rubius drug derived from red blood cells produces anti-tumor responses — and more questions
Two patients with cancer showed partial tumor shrinkage after infusions of a novel immune-boosting treatment…
STAT+: Pharmalittle: Covid-19 vaccine shortages prompt new manufacturing alliances; WHO endorses AstraZeneca shot
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: A deep dive into Eli Lilly’s tantalizing Alzheimer’s drug data
Here is some analysis and perspective, not to mention a few burning questions, about the…
STAT+: Eli Lilly releases detailed results on Alzheimer’s drug, as data divide researchers
Eli Lilly’s experimental Alzheimer’s medicine donanemab showed some of the best early results seen by…
STAT+: Bipartisan group of former FDA commissioners pushes for strong tobacco regulation
WASHINGTON — A bipartisan cadre of FDA commissioners urged the Biden administration to get tough…
STAT+: Hospitals’ push to boost Medicare pay through December faces uncertain fate in the Senate
WASHINGTON — Hospitals successfully lobbied to get a House vote next week to prolong a…
STAT+: Pharmalittle: U.S. sits on millions of AstraZeneca vaccine doses; WTO again fails to act on Covid-19 proposal
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Medicare spending on neurology drugs jumped, while number of claims barely budged
During a recent five-year period, Medicare spending on hundreds of medicines to treat various neurologic…
STAT+: Pharmalittle: Lilly fired manager who tracked employee production complaints; Denmark suspends AstraZeneca shot
Top of the morning to you, and a fine one it is. We say this…
Opinion: STAT+: Q&A with ‘Code Breaker’ author Walter Isaacson on CRISPR, patents, and more
In this week’s episode of the “First Opinion Podcast,” STAT’s Patrick Skerrett talks with journalist,…
STAT+: Antibiotic prescribing during the pandemic raises concern about drug resistance
Amid rising worries over antibiotic resistance, a new study suggests the drugs were overprescribed to…
STAT+: 4 lessons from IBM’s failure to transform medicine with Watson Health
The demise of IBM’s Watson Health would be easy to file away as another ill-fated…
.jpg)
STAT+: Pharmalittle: Biden urged by former FDA commissioners to pick agency chief; Lilly reports more positive data for Covid-19 drug
Hello, everyone, and how are you this fine, sunny morning? The middle of the week…
STAT+: Bluebird says its gene therapy was ‘very unlikely’ to be cause of patient’s cancer
Bluebird Bio said Wednesday that it was “very unlikely” that its experimental gene therapy for…
STAT+: 6 former FDA commissioners push Biden to nominate a permanent chief
WASHINGTON — Six former FDA commissioners are urging President Biden to quickly nominate an FDA…
STAT+: Pharmalittle: Covid-19 forces FDA to postpone inspections; pharma urges Biden to reject WTO proposal
Rise and shine, another busy day is on the way. We can tell it is…
STAT+: As Takeda buys Maverick for up to $525 million, R&D chief promises an ‘inflection year’
Takeda on Tuesday announced that it is buying Maverick Therapeutics for as much as $525…
STAT+: Is a leaderless FDA clamping down on drug reviews? Not knowing is weighing heavy on biotech
Seemingly overnight, the Food and Drug Administration appears to be taking a more risk-averse stance…
STAT+: With data on a cancer drug derived from red blood cells looming, Rubius Therapeutics seeks to shed its bumbling image
Rubius Therapeutics is the can’t-do-anything-right biotech spinout from the high-profile venture capital firm Flagship Pioneering….
STAT+: Biden’s silence on an FDA nominee underscores how tough it is to fill that job
WASHINGTON — Nearly everyone here expected President Biden to move with record speed to nominate…
STAT+: Drug makers urge Biden to reject proposal to waive patent rights on Covid-19 products
More than two dozen of the largest pharmaceutical companies are urging President Biden to reject…
STAT+: FDA reviews accelerated approvals as two drug makers withdraw bladder cancer indications
For the second time in less than a month, a drug maker has pulled an…
STAT+: Pharmalittle: Merck says early data shows pill is effective against Covid-19; WHO’s COVAX program ships first doses
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
Opinion: STAT+: Making pharma’s post-Covid-19 future faster and smarter
There’s nothing like a global pandemic to force a reimagining of one’s business. What it…
STAT+: ‘We are on a collision course’: As virtual care booms, experts call for new health data privacy protections
A drop in your daily step count. A missed period. A loss of hearing. If…
STAT+: Inside the fall of Watson Health: How IBM’s audacious plan to ‘change the face of health care’ with AI fell apart
It was a summer day in 2018, and the outlook could hardly have seemed more…
STAT+: CytoDyn’s wild weekend of data-mining study results ends in failure for its Covid treatment
Results from a late-stage clinical trial released late Friday by the drug maker CytoDyn showed…
STAT+: Lawmakers rail against huge tax breaks drug wholesalers get from opioid settlement
Three congressional lawmakers are examining the extent to which pharmaceutical wholesalers and a leading drug…
STAT+: European Commission probes Teva for allegedly using patents to thwart competition
In its latest bid to ensure competition among drug makers, the European Commission has opened…
STAT+: Pharmalittle: Serum CEO warns of shortage of vaccine components; EU to extend Covid-19 export scheme
And so, another working week will soon draw to a close. Not a moment too…
STAT+: What to look for in Lilly’s eagerly awaited Alzheimer’s data
Earlier this year, amid the increasingly bruising debate over Biogen’s controversial treatment for Alzheimer’s disease,…
STAT+: ‘We’re only going to cure diseases if we understand them’: Whitehead director advocates for basic science
Ruth Lehmann became director of the Whitehead Institute for Biomedical Research in July 2020. That…
STAT+: Physician and patients may prefer brand-name drugs, but they cost Medicare Part D a lot of money
Generic drugs may remain lower-cost alternatives to brand-name medicines, but the Medicare Part D program…
STAT+: Amgen spends $1.9 billion on Five Prime, eyeing an expansion in Asia
Amgen said Thursday it will purchase Five Prime Therapeutics for $1.9 billion to obtain a…